Please login to the form below

Not currently logged in
Email:
Password:

Gilead wins European approval for triple hep C combination Vosevi

The treatment brings together sofosbuvir, velpatasvir and voxilaprevir

GileadGilead Sciences has chalked up a big win with its hepatitis C treatment Vosevi (sofosbuvir/velpatasvir/voxilaprevir) as it becomes the first and only single tablet regimen for patients who have previously failed therapy with direct-acting antivirals (DAA).

The drug was approved to treat adults with genotype 1-6 chronic hepatitis virus (HCV) infection as a 12-week regimen for patients without cirrhosis or with compensated cirrhosis.

Supported by data from two phase III studies, POLARIS-1 and POLARIS-4 evaluated 12 weeks of the single tablet regimen in patients with hepatitis C genotypes 1-6 who were previously treated unsuccessfully with DAA-containing regimens, including NS5A inhibitors.

The results show that 97% of patients on Vosevi achieved the primary efficacy endpoint of a sustained viral response (SVR) for 12 or more weeks post-treatment.

John Milligan, president and chief executive officer, Gilead, said: “The authorisation of Vosevi demonstrates our ongoing commitment to bring therapies with high cure rates to all HCV-infected patients.”

The EC also approved an extension for Harvoni (ledipasvir/sofobuvir), - which was previously authorised to treat adults with chronic HCV genotypes 1, 3, 4, 5, or 6 - and will now include the treatment in adolescents aged 12 to 18 years.

This marks another win for the biopharma as Harvoni is the first DAA chronic HCV treatment to be granted an extension to treat adolescents in the European Union.

Milligan added: “We look forward to working with healthcare providers and government to ensure Vosevi is made available to patients who would benefit the most from it, while continuing to expand the benefits of our other approved medicines for patients with chronic HCV infection across Europe.”

Vosevi has already had the US Food and Drug Administration (FDA) go-ahead back in July for the re-treatment of adults with genotype 1-6 chronic HCV infection.

Article by
Gemma Jones

25th October 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics